Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid
Open Access
- 1 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (5) , 734-743
Abstract
BACKGROUND: Analyses of cerebrospinal fluid (CSF) biomarkers (β-amyloid protein, total tau protein, and hyperphosphorylated tau protein) are part of the diagnostic criteria of Alzheimer disease. Different preanalytical sample procedures contribute to variability of CSF biomarker concentrations, hampering between-laboratory comparisons. The aim of this study was to explore the influence of fractionated sampling, centrifugation, freezing temperature, freezing delay, and freeze–thaw cycles on CSF biomarker analyses. METHODS: We studied fractionated sampling in sequential aliquots of lumbar CSF. Centrifuged and noncentrifuged samples from the same fraction were compared. CSF samples were subjected to different protocols (liquid nitrogen, −80 °C, and −20 °C; 24 h at 2–8 °C; and 24 and 48 h at room temperature). To study the influence of freeze–thaw cycles, samples were thawed up to 4 times and refrozen at −80 °C. CSF was collected in polypropylene tubes. We measured CSF biomarker concentrations with commercially available single-analyte Innotest assays. RESULTS: CSF biomarker concentrations from non–blood-contaminated samples are not influenced by centrifugation or fractionated sampling. Freezing temperature and delayed storage can affect biomarker concentrations; freezing of CSF samples at −80 °C as soon as possible after collection is recommended. Consecutive freezing and thawing of CSF samples up to 3 times had little effect. CONCLUSIONS: Temperature of freezing, delay until freezing, and freeze–thaw cycles significantly influence CSF biomarker concentrations, stressing the need for standard operating procedures for preanalytical sample handling. The differences observed in this study are, however, relatively small, and the impact on the clinical value of these CSF biomarkers needs to be determined.Keywords
Funding Information
- EU Joint Programme for Neurodegenerative Disease Research
- Research Foundation Flanders
- Agency for Innovation by Science and Technology
- Belgian Science Policy Office Interuniversity Attraction Poles
- Fujirebio Europe
- Alzheimer's Biomarkers Standardization Initiative
- Institute Born-Bunge/University Antwerp
- University of Antwerp Research Fund
- Alzheimer Research Foundation
- ABSI
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115372)
This publication has 26 references indexed in Scilit:
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaThe Lancet Neurology, 2014
- CSF biomarker variability in the Alzheimer's Association quality control programAlzheimer's & Dementia, 2013
- Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An UpdateBiomarkers in Medicine, 2012
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer's & Dementia, 2011
- Rostrocaudal Dynamics of CSF BiomarkersNeurochemical Research, 2010
- Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patientsEuropean Journal of Paediatric Neurology, 2008
- Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodiesClinical Chemistry and Laboratory Medicine (CCLM), 2006
- Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical PracticeClinical Chemistry, 2005
- Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injuryNeurology, 2004
- Dynamics of brain-derived proteins in cerebrospinal fluidClinica Chimica Acta, 2001